Patient-Reported Outcomes (PROs) From the Phase 3 A.R.R.O.W. Study Comparing Once-Weekly versus Twice-Weekly Carfilzomib Dosing in Relapsed and Refractory Multiple Myeloma (RRMM) — Philippe Moreau (2018) | RDL Network
Patient-Reported Outcomes (PROs) From the Phase 3 A.R.R.O.W. Study Comparing Once-Weekly versus Twice-Weekly Carfilzomib Dosing in Relapsed and Refractory Multiple Myeloma (RRMM)
Meletios A Dimopoulos, Rubén Niesvizky, Katja Weisel, David S. Siegel, Roman Hájek, María‐Victoria Mateos, Michèle Cavo, Mei Huang, Anita Zahlten‐Kumeli, Philippe Moreau
Philippe Moreau, María‐Victoria Mateos, James R. Berenson, Katja Weisel, Antonio Lazzaro, Kevin Song, Meletios A Dimopoulos, Mei Huang, Anita Zahlten‐Kumeli, A. Keith Stewart
María‐Victoria Mateos, Philippe Moreau, James R. Berenson, Katja Weisel, Antonio Lazzaro, Kevin Song, Meletios A Dimopoulos, Mei Huang, Anita Zahlten‐Kumeli, A. Keith Stewart
Meletios A Dimopoulos, Rubén Niesvizky, Philippe Moreau, David S. Siegel, Roman Hájek, María‐Victoria Mateos, Michèle Cavo, Mei Huang, Anita Zahlten‐Kumeli, Katja Weisel
Discussion(0)
No comments yet. Be the first to comment.